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Abstract
Transcription factors that mediate neuronal defenses against diverse stresses
were quantified in plasma neural-derived exosomes of Alzheimer’s disease or
frontotemporal dementia patients and matched controls. Exosomal levels of
low-density lipoprotein receptor-related protein 6, heat-shock factor-1, and
repressor element 1-silencing transcription factor all were significantly lower in
Alzheimer’s disease patients than controls (P < 0.0001). In frontotemporal
dementia, the only significant difference was higher levels of repressor element
1-silencing transcription factor than in controls. Exosomal transcription factors
were diminished 2–10 years before clinical diagnosis of Alzheimer’s disease.
Low exosomal levels of survival proteins may explain decreased neuronal resis-
tance to Alzheimer’s disease neurotoxic proteins.
Introduction
Deficiencies of transcription factors that protect neurons
from diverse stresses have been implicated in progression
and severity of Alzheimer’s disease (AD).1,2 Repressor ele-
ment 1-silencing transcription factor (REST) is expressed
at high levels in aging human brain, where it maintains
factors that enhance neuronal resistance to stresses and
apoptosis.1,3 Nuclear levels of REST and its recognition
motif, termed RE1, are lower in autopsy brain tissues of
patients with AD than cognitively normal controls.1 A
complex of low-density lipoprotein receptor-related pro-
tein 6 (LRP6) and Frizzled receptors bind Wnt ligands
and thereby evoke nuclear translocation of b-catenin that
activates genes encoding survival factors such as REST.4–6
As for REST, LRP6-Wnt signaling is decreased in autopsy
brain tissue from AD patients and deletion of the Lrp6
gene selectively in mouse forebrain neurons enhances
AD-like pathology.2 The heat-shock factor-1 (HSF1)
maintains neuronal defenses by increasing expression of
heat-shock family chaperones and cytoskeletal-protective
calcium-sensing proteins, but has not been adequately
studied in human neurodegenerative diseases.7–9
Recent analyses of proteins extracted from immuno-
chemically isolated neurally derived plasma exosomes
have shown significantly higher levels of pathogenic P-
T181-tau, P-S396-tau and Ab1–42, as well as altered levels
of phosphorylated forms of the insulin receptor proximal
signaling protein, termed insulin receptor substrate (IRS)
in AD as contrasted with controls.10,11 Plasma neurally
derived exosomal levels of P-T181-tau, P-S396-tau, Ab1–
42, and phosphorylated forms of IRS were significantly
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different in preclinical AD (AP) than for controls up to
10 years before appearance of neurological signs.10 Here,
we demonstrate significant differences between AD
patients and controls in neural exosomal contents of
transcription factors mediating neuronal resistance to
diverse stresses.
Patients and Methods
Experimental design and patient evaluation
We identified 24 patients for cross-sectional studies (one
blood sample at the National Institute on Aging [NIA])
and 16 patients for longitudinal studies (one blood sam-
ple at diagnosis [longitudinal AD set] and another 2–
10 years earlier [longitudinal AP set] at the Mayo Clinic
or the University of Kentucky) (Table 1). Samples from
the longitudinal study were analyzed without knowledge
of any clinical data. Amnestic mild cognitive impairment
(MCI) and dementia from AD were diagnosed as
described, using established criteria.10–17 Ten patients with
the behavioral variant of frontotemporal dementia (FTD)
were from the Memory and Aging Center of the Depart-
ment of Neurology of the University of California, San
Francisco. Their diagnosis and assignment to mild or
moderate dementia groups (Table 1) were based on stan-
dard criteria.18,19 Cognitively normal control subjects for
FTD (FTC) and both AD sets (AC) were from the NIA
(28/50) or the Jewish Home of San Francisco (22/50) and
were matched by age, gender, and race to FTD and AD
patients in cross-sectional and longitudinal studies.
Each subject and some patient designates signed consent
forms approved with the protocol at each institution. Thirty
milliliter of venous blood were drawn into 100 U/mL of
heparin and centrifuged for 15 min at 2000g. Plasmas were
stored in 0.5 mL aliquots at 80°C.
Isolation of plasma exosomes for extraction
and Enzyme-Linked Immunosorbent Assay
(ELISA) quantification of exosome proteins
Two hundred fifty microliters of plasma were incubated
with 0.10 mL of thromboplastin-D (Fisher Scientific, Inc.,
Hanover Park, IL) followed by addition of 0.15 mL of
calcium- and magnesium-free Dulbecco’s balanced salt
solution (DBS2) with three-times the recommended con-
centrations of protease inhibitor cocktail (Roche Applied
Sciences, Inc., Indianapolis, IN) and phosphatase inhibi-
tor cocktail (Pierce Halt; Thermo Scientific, Inc., Rock-
ford, IL).10,11 ExoQuick (EXOQ; System Biosciences, Inc.,
Mountainview, CA) was added to 3000g supernates to
precipitate total exosomes, that were re-suspended for
immunochemical enrichment of exosomes from neural
sources.10,11
Exosomes absorbed by mouse anti-human CD171 (L1
cell adhesion molecule [L1CAM] neural adhesion pro-
tein) biotinylated antibody (clone 5G3; eBioscience, San
Diego, CA) and Streptavidin-Plus UltraLink resin
(Pierce-Thermo Scientific, Inc.) were released into 50 lL
of 0.05 mol/L acetic acid (pH 2.5) followed by addition
to 3000g supernates of 42 lL of 3% bovine serum albu-
min (BSA), 8 lL of 1 mol/L Tris-HCl (pH 8.0) and





Mean  SD (range) n
MMSE scores
Mean  SEM n
MMSE scores





AD 24 12/12 75.7  7.59 (62–92) 16 27.1  0.51 8 23.8  0.59** 0
AC 24 12/12 75.1  7.18 (62–92) 0 0 24 29.2  0.36
Mild dementia Moderate dementia Normal
FTD 10 7/3 64.5  9.13 (52–74) 6 26.8  2.14 4 17.4  2.72* 0
FTC 10 7/3 64.2  8.76 (52–74) 0 0 10 28.5  0.72
(B) Longitudinal studies
MCI Dementia Normal
AP 16 7/9 78.2  6.44 (68–88) 0 0 16 29.0  0.31
AD 16 7/9 83.8  7.54 (71–97) 7 24.0  0.90 9 21.3  1.53** 0
AC 16 7/9 78.3  5.99 (68–88) 0 0 16 28.7  0.47
The significance of differences in MMSE values between AD dementia and MCI (parts A and B), and between FTD moderate dementia and mild
dementia (part A) were calculated by an unpaired t test. MMSE, Mini-Mental State Examination; n, number of subjects; AD, Alzheimer’s disease;
MCI, mild cognitive impairment; FTD, frontotemporal dementia.
*P < 0.01 and **P < 0.001.
770 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Defective Neural Survival in Alzheimer’s Disease E. J. Goetzl et al.
0.40 mL of M-PER mammalian protein extraction
reagent (Thermo Scientific, Inc.).10,11
Neural exosomal proteins neuron-specific enolase (NS-
enolase) (R&D Systems, Inc., Minneapolis, MN), type 1
neural cell adhesion molecule (NCAM-1) (Raybiotech,
Inc., Norcross, GA) and tetraspanning exosome marker
human CD81 (Cusabio-American Research Products, Inc.,
Waltham, MA) were quantified in the linear range of ELI-
SAs. Transcription factors were quantified by ELISAs for
HSF1 (Enzo Life Sciences, Inc., Farmingdale, NY), REST
(Cusabio, American Research Products, Inc.), and LRP6
(USCN Life Science, Inc., American Research Products,
Inc.). Neural exosomal levels of CD81 (mean  SEM,
n = 40) were 5.98  0.76 ng/mL for AD patients and
5.44  0.82 ng/mL for AC controls, indicating the same
total amount of exosomes.
The mean value for all determinations of CD81 in each
assay group was set at 1.00 and the relative values for
each sample used to normalize their exosomal content. A
neural origin and enrichment of neural exosomes by anti-
L1CAM antibody absorption were supported by enhanced
content of NCAM-1 and NS-enolase (Table S1).20
Statistical analyses
The statistical significance of differences between means
for each patient group and their respective control group
was determined with an unpaired t test including a Bon-
ferroni correction (GraphPad Prism 6, La Jolla, CA). For
longitudinal analyses, the significance of differences
between AP and AD values was calculated with a paired t
test (GraphPad). Discriminant classification modeling and
receiver operating characteristic (ROC) analyses of pro-
teins in the AD versus AC cross-sectional groups were
conducted as described.10,11
Results
Transcription factor levels of plasma neural exosomes
were significantly lower for AD patients than AC control
subjects in the cross-sectional study (Fig. 1). The
mean  SEM levels of LRP6, HSF1, and REST for AD
patients (483  49.9, 102  3.96, and 47.4  8.16 pg/
mL, respectively) were significantly lower than those for
AC controls (1028  64.7, 319  32.0, and 667 
140 pg/mL) (all P < 0.0001). In contrast, there were no
significant differences in LRP6 or HSF1 between the FTD
(857  96.2 and 274  51.0 pg/mL, respectively) and
FTC (1104  94 and 341  51.4 pg/mL) groups (Fig. 1).
The REST level was significantly higher for FTD patients
(2065  162 pg/mL) than FTC controls (691  123 pg/
mL) (P < 0.0001), in contrast to earlier findings of lower
values in brain tissues.1 There were no differences
between levels of the transcription factors in AD patients
with MCI and those with dementia (Table S2). ROC
analyses of all analytes correctly classified 79% of AC sub-
jects and 92% of AD patients (Fig. S1), as had primary
pathogenic proteins.10
The results of longitudinal studies were confirmatory,
as each of the plasma neural-derived exosomal protein
levels for AD patients 2–10 years before (AP group) and
at the time of diagnosis (AD group) were significantly
lower than for AC control subjects (Fig. 2). The
mean  SEM levels of LRP6, HSF1, and REST for the
AD group (568  26.3, 140  9.75, and 13.8  1.87 pg/
mL, respectively) and for the AP group (689  23.6,
183  9.95, and 30.7  5.37 pg/mL) were significantly
lower than those for AC controls (1028  64.7,
319  32.0, and 667  140 pg/mL) (all P < 0.0001). The
respective levels for the AD group all were significantly
lower than those for the AP group (P values of 0.0019,
0.0034, and 0.0066). Thus, levels of these transcription
factors were significantly low years before appearance of
clinical signs of AD and there was continued declination
with time. There were no differences between levels of
any of the transcription factors in AP samples obtained
2–5 years before and 6–10 years before diagnosis.
Discussion
It is difficult to assign distinct contributions to each of
the pathogenic mechanisms and deficient neuronal
Figure 1. Levels of neural-derived plasma exosomal proteins in patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and
matched cognitively normal case controls (AC, FTC). The horizontal line in each cluster here and in Figure 2 depicts the mean for that set.
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defenses involved in AD. However, the low neural exoso-
mal levels of critical survival factors in AD reported here
(Figs. 1, 2) are of a degree similar to that of the increases
in neural exosomal pathogenic proteins10,11 and suggest a
loss of resistance to neurotoxic proteins that is likely to
increase susceptibility to development of AD. It also is
possible to conclude that the extent of deficiency of these
survival factors detected in neural plasma exosomes is
similar to those found in human brain tissues from
patients with AD at autopsy and analogous to those in
mouse models with targeted deletions that result in earlier
and more severe AD-like disease.1,2
The Wnt signaling pathway regulates neurogenesis and
diverse neurodevelopmental processes, as well as a variety
of synaptic functions.4 Of the transcriptional factors here
found to be deficient in AD, LRP6 is a mediator of Wnt
signaling and REST is a Wnt signal target.1,2,5,6 Thus, a
deficiency in LRP6 which diminishes Wnt signaling may
contribute to reduced nuclear localization and activation
of REST.
Major survival factor deficiencies 2–10 years before
appearance of diagnostic clinical signs of AD (Fig. 2) sug-
gest a possible early pathogenic contribution of increased
neuronal susceptibility to neurotoxic proteins in AD
beyond higher levels of the pathogenic proteins.10,11 Vali-
dation of this platform will require larger studies analyz-
ing profiles of these factors for individual patients and
correlating results with those of cerebral bioimaging and
pathology.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. ROC plots depicting distinctions between AD
and AC. Discriminant classifier analysis attained a Wilk’s
Lambda of 0.395 and an exact F of 34.417 (P < 0.0001),
and correctly classified 79% of AC subjects and 92% of
AD patients. Of the proteins assessed, all had asymptotic
significance <0.001 and achieved excellent classification in
a rank order of REST (area under the curve [AUC]
0.944), HSF1 (AUC 0.944), and LRP6 (AUC 0.924).
Table S1. Immunochemical enrichment of neuronal
markers in plasma exosomes. Each pg/mL value is the
mean  SEM of determinations for five plasma samples
from AD patients or matched AC controls after normali-
zation for CD81 content. NCAM-1, type 1 neural cell
adhesion molecule; L1CAM, L1 cell adhesion molecule;
NS-enolase, neuron-specific enolase. As a mean of ~8% of
total precipitated plasma exosomes are neurally
derived10,20 this mean 10-fold enrichment suggests that
up to 80% of the “neural set” studied are of neural ori-
gin.
Table S2. Levels of serum exosome proteins in relation to
severity of dementia in AD. All values are mean  SEM,
pg/mL. None of the differences between values for the
MCI and dementia groups was significant.
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